Decreased miR-1305 expression is associated with tumour invasiveness and poor prognosis in glioma patients

Gliomas are highly prevalent and lethal primary malignant tumours of the central nervous system. MicroRNA plays a tumour-suppressive role in various tumours, including glioma. This study aims to elucidate the expression profile, clinical relevance, biological roles, and underlying mechanisms of miR-1305 in glioma.

Tumour tissues alongside their matched normal counterparts were acquired from 105 individuals with glioma. The expression of miR-1305 was quantified using RT‑qPCR. The relationship between miR-1305 expression, clinicopathological characteristics, and prognosis was assessed through Kaplan‑Meier analysis and Cox regression. The proliferative, migratory, and invasive capacities of glioma cells following miR-1305 modulation were assessed using CCK‑8 and Transwell assays. Potential target genes of miR-1305 were predicted via bioinformatics analysis, and the direct targeting interactions were subsequently confirmed by dual-luciferase reporter assays.

A significant downregulation of miR-1305 was observed in glioma tissues. Low expression of miR-1305 was associated with increased tumour size, poorer KPS score, and higher WHO tumour grade (p < 0.05). Patients exhibiting low miR-1305 levels experienced decreased overall survival; multivariate analysis identified this marker as an independent prognostic factor. Functional assays showed miR-1305 overexpression inhibited glioma cell proliferation, migration, and invasion. Mechanistically, WNK3 was a direct target of miR-1305, exhibited inverse correlation in glioma, and its overexpression rescued miR-1305-mediated suppression of malignant phenotypes.

Low miR-1305 expression is associated with an adverse prognosis in glioma; it exerts tumour-suppressive effects by targeting WNK3 and inhibiting disease progression.